Anti-Obesity Agents
- Name
- Anti-Obesity Agents
- Accession Number
- DBCAT000472
- Description
Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.
- Drugs
Drug Drug Description Phentermine A sympathomimetic anorectic agent used as a short-term adjunct therapy that is included in a regimen of weight reduction in cases of exogenous obesity. Topiramate An anticonvulsant drug used in the control of epilepsy and in the prophylaxis and treatment of migraines. Phenylpropanolamine A sympathomimetic that was previously used in nasal decongestants and weight loss products, but has been withdrawn by the FDA due to safety risks and lack of efficacy. Phenmetrazine Used as an anorectic in the treatment of obesity. Diethylpropion An appetite suppressant used for the short term treatment of exogenous obesity in addition to calorie restriction. Orlistat A reversible inhibitor of gastrointestinal lipases indicated for weight loss and weight maintenance. Sibutramine A norepinephrine, serotonin and dopamine reuptake inhibitor indicated to assist with weight loss in obesity. Cathine Used to decrease appetite. Oleoyl-estrone For the treatment of obesity. Benfluorex Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended... Setmelanotide Setmelanotide is indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies or Bardet-Biedl syndrome. Exenatide A GLP-1 agonist used in the management of type 2 diabetes mellitus. Rimonabant For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated... Cetilistat Investigated for use/treatment in obesity. Aclimostat Aclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes). Amlintide A medication used in combination with corticosteroids for the treatment of hemorrhoids. Perflubron Investigated for use/treatment in cardiac surgery, hemorrhage, and ileus. - Drugs & Drug Targets